A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

• Status: Completed
• Trial end date: 2016-11-16
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Ticagrelor

Criteria

Inclusion Criteria:

• Confirmed medical history or diagnosis of homozygous sickle cell (HbSS) or sickle beta-zero-thalassaemia (HbS/β0) by HPLC

• If treated with hydroxyurea, the dose must have been stable for 3 months

Exclusion Criteria:

• History of transient ischaemic attack or clinically overt cerebrovascular accident

• Moderate or severe hepatic impairment

• Treatment with chronic red blood cell transfusion therapy

• Pre-dominate cause of pain is not sickle cell disease related

• Chronic treatment with anticoagulants or antiplatelet drugs.